Ultimate Guide to Rocket Lab (RKLB) Stock Price History & Outlook

Ultimate Guide to Rocket Lab (RKLB) Stock Price History : Welcome to rostneo.com’s in-depth analysis of Rocket Lab Corporation (NASDAQ: RKLB)—America’s rising star in small and medium satellite launch services. In this article, you’ll discover RKLB’s price journey, financial health, growth drivers, and what analysts expect next. It’s SEO-engineered with key terms like “Rocket Lab stock analysis,” “RKLB price history.

2. Rocket Lab at a Glance

• Founded: 2006 by Sir Peter Beck in New Zealand; now headquartered in Long Beach, California .
• Public Listing: Went public via a SPAC merger in August 2021 with Vector Acquisition Corp, at a $4.8B valuation .
• Core Products:
  • Electron small-lift rocket—66 launches, 62 successes .
  • Neutron medium-lift reusable rocket—aiming for first flight in 2H 2025 .
  • Satellite components & Photon spacecraft bus .

---

3. Price History & Volatility

🎯 5-Year Snapshot

According to Macrotrends, here’s how RKLB has performed:

Year	Price Range	Year-End	Annual % Change
2020	–	–	IPO prep
2021	$9.90–20.72	$12.28	+21%
2022	$3.56–12.20	$3.77	–69%
2023	$3.67–7.93	$5.53	+47%
2024	$3.53–28.44	$25.47	+361%
YTD 2025	$16.37–33.46	$32.35	+27%

• 2022 Washout: Stock plunged nearly 70% amid market-wide sell-off .
• 2024–25 Rally: A spectacular rebound, fueled by strong launches, contracts, and Neutron optimism.

📅 Recent Daily Moves

From Investing.com (May–June 2025):

• June 26: Closed at $36.13 (+11.7%)
• June 24: All-time high close at $33.46
• 52-week range: Low ~ $4.20 → High ~ $37.20 .

📊 Volatility & Beta

• Beta: ~ 2.6 → highly sensitive to market swings .
• Volatility: ~ 15%, making it a rollercoaster pick .

---

4. Financial Performance

HIMS Stock Prediction 2025: Can Hims & Hers Health Inc (HIMS) Be the Next Big Growth Stock?

HDB Financial Services IPO GMP Today: What Investors Need to Know Before the Big Debut (2025)

Stimulus Check 2025 Update: Who’s Eligible, When You’ll Get It, and What to Expect

Stimulus Check 2025 Update: Who’s Eligible, When You’ll Get It, and What to Expect

Q1 2025 Highlights

Business Wire reports:

• Revenue: $123M, up 32% YoY
• EPS: –$0.12 per share (vs –$0.11 est.)
• Cash Position: ~$430M–$504M
• Q2 2025 Guidance: $130M–$140M; Full-year outlook of > $900M.

Profitability & Margins

Nasdaq’s Trefis analysis highlights:

• P/S Ratio: 35.7× (vs 3.1× S&P 500)
• Operating Margin: –44%
• Operating Cash Flow Margin: –21.6%
• Net Income Margin: –44.3%
• Debt-to-Equity: ~3.4% → conservative leverage .

Balance Sheet Health

• Cash/Assets Ratio: ~34% .
• High cash buffer, but burning ~$170M this year; runway into 2026 .

---

5. Major Growth Catalysts

A. Neutron Rocket & NSSL Contracts

• Neutron aims to carry ~13,000 kg to LEO, debuting 2H 2025 .
• On-ramped to U.S. Space Force’s $5.6B NSSL Phase 3 Lane 1 program and awarded $5M task order .

B. Hypersonic & Defense Deals

• Selected for Air Force & UK hypersonic contracts under HASTE program. Stock jumped ~13% on announcement .

C. Satellite & Space Systems Expansion

• Key acquisitions: Mynaric (laser communications) & Geost (satellite sensors) .
• Airbus and Synspective multi-launch agreements, plus support for NASA & ESA missions .

---

6. Risks & Counterviews

Overvaluation Concerns

• Trefis/ Nasdaq warn valuation is stretched compared to fundamentals .
• Market correction in May 2025 post-earnings despite strong revenue .

Neutron Schedule Delays

• Bleecker Street Research questions mid-2025 launch timeline—delays possible into 2026-27, raising cash needs ~$300–600M .

Competitive Pressure

• Electron losing share to SpaceX’s Falcon 9 rideshare model. Neutron must justify high cost & compete with incumbents .

---

7. Analyst Sentiment & Price Targets

• Trefis (Nasdaq): Cautions overvaluation, but notes strong deal flow .
• Bleecker Street: Bearish due to Neutron delays & funding risks .
• Morgan Stanley: Pushed target to $20 in April, citing launch momentum .
• Barron’s & Stifel (Erik Rasmussen): Rated Buy with $29 target; expect EBITDA positive by 2026 .
• Cantor Fitzgerald: Overweight; flagged as space economy beneficiary amid U.S. policy tailwinds .

Conclusion

Rocket Lab has powered through a dramatic journey—from sub-$4 lows to over $36 highs—on the strength of a rapidly expanding space-tech playbook. Revenue growth, critical contracts, and a bold Neutron roadmap paint a compelling long-term narrative. But lofty valuations, execution drag, and fierce competition pose dangers.

For long-term, growth-oriented investors:

• RKLB can be a high-risk, high-reward asset tied to space exploration and defense dynamics.

For risk-averse investors:

• Consider waiting for valuation signs of compression or verified Neutron launch milestones.